A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
ApexOnco Front Page
Recent articles
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
The group expects to raise nearly $170m.
Can the company add a Car-T string to its stem cell transplant bow?
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
